Liposomal formulations of anthracycline antibiotics

   
Berezov T.T.1, Yaglova N.V.1, Chekhonin V.P.2, Zhirkov Yu.A.2

1. Peoples' Friendship University
2. Serbsky National Research Centre for Social and Forensic Psychiatry
Section: Review
PubMed Id: 15628591
Year: 2004  Volume: 50  Issue: 5  Pages: 412-419
Anthracycline antibiotics with significant antitumor activity are widely used for treatment of various oncologic diseases in spite of their poor pharmacokinetics and severe side-effects. To improve the efficacy of treatment of oncologic patients, liposomal formulations of the anthracycline antibiotics, such as Doxil, TLC D-99, and DaunoXome, have been developed. Pharmacokinetic parameters of liposomal doxorubicin and daunorubicin differ markedly from the parameters of their free formulations. Liposomal anthracyclines display a prolonged circulation time, reduced clearance, smaller volume of distribution, and lower toxicity. Doxil and DaunoXome have been licensed for treatment of AIDS-related Kaposi's sarcoma. Entrapment of anthracycline antibiotics into liposomes coupled with monoclonal antibodies enhances their uptake by tumor cells.
Download PDF:
Reference:

Berezov T.T., Yaglova N.V., Chekhonin V.P., Zhirkov Yu.A. (2004) Biomeditsinskaya khimiya, 50(5), 412-419.
References  
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)
        

© Institute of Biomedical Chemistry, Moscow, Russia